TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32020863

Group type: EXPERIMENTAL
Intervention: Self-care education intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 91
Study: 35617320

Group type: EXPERIMENTAL
Intervention: Lower limbs (LL) endurance training program for 18 sessions (3 sessions/week for 6 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Upper limbs, lower limbs, and breathing exercises (ULB) program for 18 sessions (3 sessions/week for 6 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (11 patients who refused to participate in the ET program)
Number of subjects: 31
Study: 34174914

Group type: EXPERIMENTAL
Intervention: HD-tDCS at 1.5 mA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HD-tDCS at 2 mA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 34848312

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (1 µg.kg‐1 loading, 0.6 µg.kg‐1.h‐1 infusion)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lignocaine-dexmedetomidine infusion (1.5 mg.kg‐1 loading, 2 mg.kg‐1.h‐1 infusion and 1 µg.kg‐1 loading, 0.5 µg.kg‐1.h‐1 infusion)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lignocaine infusion (1.5 mg.kg‐1 loading, 2 mg.kg‐1.h‐1 infusion)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (10 mL loading, 1 mL.kg‐1.h‐1 infusion)
Number of subjects: 96
Study: 32576496

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 32675432

Group type: EXPERIMENTAL
Intervention: Tomographic neurofeedback (TONF)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional electrode-based neurofeedback (NTNF)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (TONF and NTNF)
Number of subjects: 48
Study: 36080405

Group type: EXPERIMENTAL
Intervention: Liquid crystalline oligomers polymerized in freely suspended aqueous media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reactive liquid crystalline monomers oligomerized in a micro-channel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micro-confinement in a top-down microfabricated mold
Number of subjects: 0
Study: 34567960

Group type: EXPERIMENTAL
Intervention: 4-weekly BTA treatment
Number of subjects: 263

Group type: COMPARATOR
Intervention: 12-weekly BTA treatment
Number of subjects: 263
Study: 33171597

Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (2 g once daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (2 g once daily)
Number of subjects: 68
Study: 34841995

Group type: EXPERIMENTAL
Intervention: Nordic hamstring and sprint exercises (EG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 49
Study: 34086485

Group type: EXPERIMENTAL
Intervention: Technology-facilitated self-management support with weekly automated interactive voice response telephone calls for 12 months
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Technology-facilitated self-management support
Number of subjects: 204

Group type: COMPARATOR
Intervention: Enhanced usual care with printed generic self-management instructions
Number of subjects: 204
Study: 35316144

Group type: EXPERIMENTAL
Intervention: New heat and moisture exchangers (HMEs) and adhesives
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 40
Study: 32993326

Group type: EXPERIMENTAL
Intervention: Woodcast (WCG)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Dynacast (DNG)
Number of subjects: 170
Study: 33546885

Group type: EXPERIMENTAL
Intervention: CyclAGel 0.05%/QD
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CyclAGel 0.05%/BID
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CyclAGel 0.1%/QD
Number of subjects: 240

Group type: COMPARATOR
Intervention: Restasis 0.05%/BID
Number of subjects: 240
Study: 36228432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33430808

Group type: EXPERIMENTAL
Intervention: Carboplatin/gemcitabine (2 cycles)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (breast surgery without carboplatin/gemcitabine)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Total study population
Number of subjects: 52
Study: 33186309

Group type: EXPERIMENTAL
Intervention: Home-Initiated-Programme-to-Prepare-for-Operation (HIPPO) including an animated video and activity sheets
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Home-Initiated-Programme-to-Prepare-for-Operation (HIPPO)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard pre-operative workflow (Control)
Number of subjects: 130
Study: 33121507

Group type: EXPERIMENTAL
Intervention: Rad-score (radiomics signature)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Nomogram model incorporating Rad-score and clinical staging
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 226
Study: 35428364

Group type: EXPERIMENTAL
Intervention: Rapid chest compression technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive hallux mobilization (Control)
Number of subjects: 0
Study: 34001024

Group type: EXPERIMENTAL
Intervention: Ambient bright light treatment (1000 lx, 6000 K from 10:00 to 15:00)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo condition (continuous standard light levels 150-300 lx, 3000 K)
Number of subjects: 69
Study: 32787848

Group type: EXPERIMENTAL
Intervention: Vaginally administered conjugated estrogens tablet (0.625 mg, daily for 3 weeks then twice weekly for 9 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 33735517

Group type: EXPERIMENTAL
Intervention: Biofeedback relaxation (BR) during LA administration
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Audio-visual (AV) distraction during LA administration
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both interventions (BR and AV)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Biofeedback relaxation (BR)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Audio-visual (AV) distraction (AV)
Number of subjects: 70
Study: 35084038

Group type: EXPERIMENTAL
Intervention: Mat Pilates (MP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mat Pilates plus Aerobic Exercise (MP + AE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study: 33620880

Group type: EXPERIMENTAL
Intervention: Negative-pressure isolation mask during gastroscopy
Number of subjects: 316

Group type: COMPARATOR
Intervention: Conventional group (no mask)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Negative-pressure isolation mask
Number of subjects: 316
Study: 35787813

Group type: EXPERIMENTAL
Intervention: 30-h communication skills training (CST)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 90
Study: 32115032

Group type: EXPERIMENTAL
Intervention: Low dose of NAM (50 mg/kg)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: High dose of NAM (100 mg/kg)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Low dose of BA (500 mg/kg)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: High dose of BA (1,000 mg/kg)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Compound supplement (50 mg/kg NAM + 500 mg/kg BA)
Number of subjects: 567

Group type: COMPARATOR
Intervention: High stocking density control group (HD)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Low stocking density control group (LD)
Number of subjects: 567
Study: 35503488

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham-TEA
Number of subjects: 30
Study: 33577105

Group type: EXPERIMENTAL
Intervention: Supinated wrist position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neutral wrist position
Number of subjects: 10
Study: 32988502

Group type: EXPERIMENTAL
Intervention: Brown hens
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: White hens
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: All strains
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Upper tier occupancy at night
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Perch occupancy
Number of subjects: 576
Study: 35947362

Group type: EXPERIMENTAL
Intervention: Alert group (risk of 1-year mortality calculated and presented to clinicians)
Number of subjects: 3124

Group type: COMPARATOR
Intervention: Usual-care group (no risk assessment provided)
Number of subjects: 3124
Study: 34070910

Group type: EXPERIMENTAL
Intervention: Oral native vitamin D3 at a dose of 2000 IU once a day for 12 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 33
Study: 34925697

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) intervention: blood pressure cuff inflated to 200 mmHg for 5 minutes, repeated four times with 5-minute perfusion between cycles.
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sham intervention: blood pressure cuff inflated to 20 mmHg, performed similarly to RIPC.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 111
Study: 32289824

Group type: EXPERIMENTAL
Intervention: Olfactory training with four odors (rose, vanilla, chocolate, peach) every two hours for four weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: No olfactory training (control group)
Number of subjects: 42
Study: 34801470

Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor Fibrin (CGF)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (serum)
Number of subjects: 118
Study: 616769489

Group type: EXPERIMENTAL
Intervention: Quiet atmosphere during SCT assessment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Noisy atmosphere during SCT assessment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quiet atmosphere for year 1 and 2 residents
Number of subjects: 42

Group type: COMPARATOR
Intervention: Noisy atmosphere for year 3 and 4 residents
Number of subjects: 42
Study: 34555481

Group type: EXPERIMENTAL
Intervention: Low dose secukinumab (75/75/150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose secukinumab (75/150/300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical placebo
Number of subjects: 0
Study: 33762414

Group type: EXPERIMENTAL
Intervention: Recombinant adjuvanted vaccine (RZV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live-attenuated vaccine (ZVL)
Number of subjects: 0
Study: 32542650

Group type: EXPERIMENTAL
Intervention: Intercropping with Vulpia myuros
Number of subjects: 0

Group type: COMPARATOR
Intervention: Black plastic film
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weed barrier fabric
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rice straw mulch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clean tillage
Number of subjects: 0
Study: 35637437

Group type: EXPERIMENTAL
Intervention: Head-elevated position
Number of subjects: 64
Study: 34019649

Group type: EXPERIMENTAL
Intervention: Vergence exercises for 6 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Accommodation exercises for 6 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vergence exercises
Number of subjects: 44

Group type: COMPARATOR
Intervention: Accommodation exercises
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vergence exercises and Accommodation exercises
Number of subjects: 44
Study: 36266099

Group type: EXPERIMENTAL
Intervention: Dual-energy CT (group D)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Single-energy CT (group S)
Number of subjects: 682
Study: 33472477

Group type: EXPERIMENTAL
Intervention: Short-segment titanium alloy posterior instrumentation (Study group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No orthopedic surgery (Control group)
Number of subjects: 50
Study: 32706681

Group type: EXPERIMENTAL
Intervention: Guaranteed incentive (US $10)
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Lottery incentive (US $50 weekly lottery drawing)
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Preferred method (guaranteed or lottery)
Number of subjects: 1517

Group type: COMPARATOR
Intervention: Control group (no incentive mentioned)
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1517
Study: 35699377

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 35863694

Group type: EXPERIMENTAL
Intervention: Walk Buds walking programme
Number of subjects: 130

Group type: COMPARATOR
Intervention: Exercise as usual
Number of subjects: 130
Study: 33491811

Group type: EXPERIMENTAL
Intervention: iSupport online caregiver skills training and support program; n=74
Number of subjects: 151

Group type: COMPARATOR
Intervention: Education-only e-book program; n=77
Number of subjects: 151
Study: 32401873

Group type: EXPERIMENTAL
Intervention: Rothbaum cognitive behavioral therapy protocol (individual treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rothbaum cognitive behavioral therapy protocol (group treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rothbaum cognitive behavioral therapy protocol (both individual and group formats)
Number of subjects: 70
Study: 35346332

Group type: EXPERIMENTAL
Intervention: Levetiracetam plus temozolomide chemotherapy for 34 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo tablets plus temozolomide for 34 weeks
Number of subjects: 142
Study: 32585438

Group type: EXPERIMENTAL
Intervention: In-bed cycling (30 min daily) in addition to usual-care physiotherapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual-care physiotherapy
Number of subjects: 74
Study: 35599463

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation of the sacroiliac joint (6 sessions)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Electrotherapy (15 sessions)
Number of subjects: 37
Study: 34282232

Group type: EXPERIMENTAL
Intervention: Highly myopic group
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-highly myopic group
Number of subjects: 170
Study: 35562373

Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19)
Number of subjects: 2584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2584
Study: 35799138

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33988071

Group type: EXPERIMENTAL
Intervention: Auto-HCT
Number of subjects: 277

Group type: COMPARATOR
Intervention: Allo-HCT
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 277
Study: 33028675

Group type: EXPERIMENTAL
Intervention: Baricitinib (once-daily oral dosing)
Number of subjects: 2387
Study: 34773803

Group type: EXPERIMENTAL
Intervention: Berberine (900 mg per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Berberine and Placebo
Number of subjects: 65
Study: 32599716

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.0055 g·kg−1 post training set)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (0.0055 g·kg−1 post training set)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (Creatine and Placebo)
Number of subjects: 22
Study: 35157829

Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg orally twice daily for 24 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 26
Study: 34235415

Group type: EXPERIMENTAL
Intervention: ALRV5XR
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 32972289

Group type: EXPERIMENTAL
Intervention: 500 mg oral clarithromycin twice a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: 20 mg/kg/day systematic glucantime
Number of subjects: 20
Study: 33081762

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Traditional operation
Number of subjects: 236
Study: 35267027

Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 32691120

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg orally
Number of subjects: 200

Group type: COMPARATOR
Intervention: Celecoxib 200 mg orally
Number of subjects: 200
Study: 34326131

Group type: EXPERIMENTAL
Intervention: GEN-1 (IL12 plasmid) administered in eight weekly intraperitoneal infusions starting at cycle 1 week 2 in combination with three 21-day cycles of NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GEN-1 (IL12 plasmid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2
Number of subjects: 18
Study: 35257062

Group type: EXPERIMENTAL
Intervention: Lumasiran (lumasiran/lumasiran group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Lumasiran (placebo/lumasiran group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lumasiran (both groups)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 37
Study: 34939363

Group type: EXPERIMENTAL
Intervention: Jujube syrup (10 cc per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo syrup (10 cc per day)
Number of subjects: 17
Study: 32597615

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 48
Study: 35451020

Group type: EXPERIMENTAL
Intervention: 25% dextrose (0.5 mL orally)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 24% sucrose (0.5 mL orally)
Number of subjects: 64
Study: 33667495

Group type: EXPERIMENTAL
Intervention: Nasal nocturnal oxygen supplementation (NOS) at 2 L/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham oxygen (ambient air)
Number of subjects: 40
Study: 32044621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg plus Hyoscine‐N‐Butylbromide 10 mg
Number of subjects: 217
Study: 35293520

Group type: EXPERIMENTAL
Intervention: CBD (300 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 32186246

Group type: EXPERIMENTAL
Intervention: Multicap (capsule containing aspirin, atenolol, ramipril, and simvastatin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (separate pills for each drug)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multicap
Number of subjects: 100
Study: 33181323

Group type: EXPERIMENTAL
Intervention: Active compression during defibrillation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard anterior-posterior defibrillation
Number of subjects: 100
Study: 32200403

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of face M1 after presentation of a happy face
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of hand M1 after presentation of a sad face
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) of face M1 after presentation of a neutral face
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of face M1 after presentation of a sad face
Number of subjects: 30
Study: 36377106

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 33251914

Group type: EXPERIMENTAL
Intervention: Early-initiated oral anticoagulation (OAC) prescribed within 30 days after surgery to 1,770 patients (24.0% of those with POAF)
Number of subjects: 24523

Group type: EXPERIMENTAL
Intervention: Patients with POAF
Number of subjects: 24523

Group type: COMPARATOR
Intervention: Patients without POAF
Number of subjects: 24523
Study: 32788487

Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 14
Study: 35436914

Group type: EXPERIMENTAL
Intervention: aerobic physical activity and muscle strengthening exercise
Number of subjects: 196

Group type: COMPARATOR
Intervention: muscle strengthening exercise only
Number of subjects: 196
Study: 33640067

Group type: EXPERIMENTAL
Intervention: Screening plus Eave Tubes (10% wettable powder formulation of β‐cyfluthrin)
Number of subjects: 2560

Group type: COMPARATOR
Intervention: Control group (insecticide-treated nets only)
Number of subjects: 2560

Group type: EXPERIMENTAL
Intervention: Screening plus Eave Tubes
Number of subjects: 2560
Study: 32389076

Group type: EXPERIMENTAL
Intervention: Weight-activated braking knee
Number of subjects: 10
Study: 36038881

Group type: COMPARATOR
Intervention: Daily Caloric Restriction (DCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IMF)
Number of subjects: 0
Study: 34515902

Group type: EXPERIMENTAL
Intervention: Simultaneous achievement of ACR50 and PASI100 response
Number of subjects: 566

Group type: COMPARATOR
Intervention: ACR50 response only
Number of subjects: 566

Group type: COMPARATOR
Intervention: PASI100 response only
Number of subjects: 566

Group type: COMPARATOR
Intervention: Did not achieve ACR50 or PASI100 response
Number of subjects: 566
Study: 35404015

Group type: EXPERIMENTAL
Intervention: DS-8895a at 1 mg/kg (Cohort 1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: DS-8895a at 3 mg/kg (Cohort 2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 89Zr-DS-8895a
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: DS-8895a
Number of subjects: 9
Study: 33249810

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma separation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no platelet separation)
Number of subjects: 60
Study: 36364963

Group type: EXPERIMENTAL
Intervention: Diet therapy (protein 1.2−1.5 g/kg) and probiotics for two months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group without diet therapy and probiotics
Number of subjects: 200
Study: 33076888

Group type: EXPERIMENTAL
Intervention: Corticosteroid trigger point injection (TPI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 54